Oncolytic viruses (OVs) are promising candidates for innovative cancer treatment technologies. We developed an original platform technology of “Conditionally replicating adenovirus that regulated with multiple factors” (m-CRA) for efficiently developing the next-generation OVs. Survivin-responsive m-CRAs (Surv.m-CRAs), which we developed using the technology, demonstrated the innovative therapeutic effects, including the potent effectiveness against most of malignant tumors in the strictly cancer-specific (safe) manner and the increased effectiveness against cancer stem cells, which are resistant to conventional therapies. After manufacturing GMP products and preforming GLP nonclinical studies in accordance with ICH guidelines, we completed the First-In-Human phase I clinical trial of Surv.m-CRA-1 (no transgene) for malignant tumors in bone or soft tissue region and cofirmed the high safety and the remarkable effectiveness. Currently, we are performing two Phase II clinical trials of Surv.m-CRA-1 for malignant bone tumors toward approval and for pancreatic cancer. Moreover, we are performing nonclinical development of Surv.m-CRA-2 (armed with a cytokine gene), which more strongly induced systemic antitumor immunity, and developing further novel technologies. In this lecture, I would like to present mainly these projects and also briefly growth factor gene therapy for intractable diseases and viral vector technology for pluripotent stem cell-based regenerative medicine.